Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERGOSTAT vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ergostat (ergotamine) is a serotonin (5-HT) receptor agonist, specifically at 5-HT1B and 5-HT1D receptors, leading to cranial vasoconstriction and inhibition of neurogenic inflammation. It also has partial agonist/antagonist activity at alpha-adrenergic receptors.
Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.
FDA-approved: Acute treatment of migraine headache with or without aura,Off-label: Cluster headache, vascular headache
Management of mild to moderate pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate,Off-label: acute pain, chronic pain
0.2 mg intramuscularly or intravenously every 2-4 hours for maximum 5 doses; not to exceed 1 mg total dose.
1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
Terminal half-life is 2–3 hours (intravenous) and 2–4 hours (oral). Short half-life necessitates frequent dosing; duration of action limited to 2–4 hours.
Acetaminophen: 2-3 hours (normal), prolonged in hepatic impairment. Caffeine: 3-6 hours (adults), prolonged in liver disease or with oral contraceptives. Dihydrocodeine: 3.5-6 hours (terminal). Clinical context: q6h dosing interval appropriate; accumulation risk in renal/hepatic impairment.
Primarily hepatic via CYP3A4. Undergoes extensive first-pass metabolism.
Acetaminophen: primarily hepatic via glucuronidation and sulfation; minor CYP2E1, CYP1A2, CYP3A4. Caffeine: hepatic via CYP1A2. Dihydrocodeine: O-demethylation to dihydromorphine via CYP2D6; also via CYP3A4.
Primarily hepatic (biliary-fecal) elimination: ~90% of a dose is excreted in feces as metabolites; renal excretion accounts for <5% unchanged drug.
Acetaminophen: renal excretion of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%), <5% unchanged. Caffeine: renal excretion of metabolites (1-methyluric acid, 1-methylxanthine, etc.), <2% unchanged. Dihydrocodeine: renal excretion of metabolites (dihydrocodeine-6-glucuronide, nordihydrocodeine, dihydromorphine), ~20% unchanged. Overall, predominantly renal (≥85%), minor biliary/fecal.
~65% bound to plasma albumin. Metabolites are less extensively bound.
Acetaminophen: 10-25% (albumin). Caffeine: 25-36% (albumin). Dihydrocodeine: ~20-30% (albumin and α1-acid glycoprotein).
Approximately 0.2–0.3 L/kg, indicating primarily extracellular and peripheral tissue distribution with limited CNS penetration.
Acetaminophen: 0.7-1.0 L/kg. Caffeine: 0.5-0.8 L/kg. Dihydrocodeine: 1.0-1.5 L/kg. Clinical meaning: moderate distribution, potential for central nervous system penetration.
Oral: ~10–20% (extensive first-pass metabolism); Sublingual: ~50–60% (avoids portal circulation); Rectal: ~30–40% (variable).
Acetaminophen: oral 75-85%. Caffeine: oral ~100%. Dihydrocodeine: oral ~20-30% (first-pass metabolism; extended-release formulations have altered bioavailability).
No specific adjustment; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-30 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; avoid in severe impairment due to dihydrocodeine accumulation.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval to every 8 hours; Child-Pugh C: avoid use due to acetaminophen hepatotoxicity and dihydrocodeine accumulation.
Intravenous: 0.1 mg/m² body surface area every 2-4 hours, maximum 0.5 mg total; intramuscular: 0.2 mg every 2-4 hours, maximum 1 mg.
Not recommended for children under 12 years due to dihydrocodeine risks; for adolescents 12-18 years: 1 tablet orally every 4-6 hours as needed, maximum 4 tablets per day (weight-based dosing not established).
Start at 0.1 mg intramuscularly or intravenously; monitor for hypertension with higher doses.
Initiate with 1 tablet orally every 6 hours; caution due to increased sensitivity to opioids and hepatotoxicity from acetaminophen; maximum 4 tablets per day; monitor renal and hepatic function.
Concomitant use with strong CYP3A4 inhibitors (e.g., protease inhibitors, macrolide antibiotics, azole antifungals) can lead to serious and/or life-threatening peripheral ischemia and vasospasm. Avoid coadministration.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen can cause fatal hepatotoxicity; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of ischemia (peripheral, cerebral, coronary) especially with prolonged use or overdose,Fibrotic complications (cardiac valvulopathy, pulmonary, retroperitoneal fibrosis) with chronic use,Medication overuse headache (MOH) with frequent use, Avoid in patients with uncontrolled hypertension, coronary artery disease, or peripheral vascular disease,Do not exceed recommended dosage; may cause ergotism
Addiction, abuse, and misuse; respiratory depression; acetaminophen hepatotoxicity; drug interaction with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; risk of serotonin syndrome; severe hypotension; adrenal insufficiency; use in patients with head injury or increased intracranial pressure; seizures; avoid in patients with severe hepatic impairment.
Concurrent use of potent CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, ketoconazole, ritonavir)
Hypersensitivity to any component; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; concomitant use with MAOIs or within 14 days; severe hepatic impairment.
Avoid grapefruit juice as it may increase ergonovine levels. No other significant food interactions.
Avoid alcohol; may increase risk of hepatotoxicity and CNS depression. High-fat meals may delay absorption but do not significantly affect overall exposure. Caffeine-containing foods and beverages may increase stimulant effects.
Ergostat (ergonovine) is contraindicated in pregnancy due to its potent uterotonic effects, which can cause uterine tetany, fetal hypoxia, and placental abruption. It is classified as FDA Pregnancy Category X. Use in the first trimester may increase the risk of spontaneous abortion; in the second and third trimesters, it can precipitate preterm labor and fetal distress. There is no evidence of structural teratogenicity from direct drug effects, but the potential for ischemic injury to the fetus due to uterine hyperstimulation exists.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data on malformations. Dihydrocodeine: Opioid; first trimester: increased risk of neural tube defects (OR 2.0-2.5); third trimester: risk of neonatal opioid withdrawal syndrome (NOWS). Overall, combination product should be used only if benefit outweighs risks.
Ergonovine is excreted into breast milk. The M/P ratio is not well established, but small amounts are detectable. It may cause adverse effects in the nursing infant, including vomiting, diarrhea, and transient hypertension. Because of the risk of ergotism in the infant, breastfeeding is generally not recommended during therapy. A decision should be made to discontinue breastfeeding or discontinue the drug, considering the importance of the drug to the mother.
Acetaminophen: Excreted in breast milk (M/P ratio ~0.9); safe at therapeutic doses. Caffeine: Excreted (M/P ~0.5-0.8); moderate intake (<300 mg/day) generally safe. Dihydrocodeine: Excreted in low levels; however, interindividual variability in metabolism (CYP2D6) may lead to higher morphine concentrations in some infants; risk of neonatal respiratory depression. M/P ratio not well established for dihydrocodeine. Use with caution, monitor infant for sedation and feeding difficulties.
No dosing adjustments are recommended or studied because use in pregnancy is contraindicated. If exposure occurs accidentally or for life-threatening indications (e.g., severe postpartum hemorrhage), the same doses used in non-pregnant adults (0.2 mg IM or IV) may be employed, but with extreme caution due to heightened sensitivity to uterotonic effects. No pharmacokinetic studies in pregnancy exist; however, increased plasma volume and altered hepatic metabolism may require careful titration, but no specific evidence supports dose changes.
No specific dose adjustments for pregnancy due to lack of pharmacokinetic studies for this combination. However, note: Increased clearance of acetaminophen in pregnancy may require higher doses for analgesia but remains within standard limits. Caffeine clearance decreases in third trimester; consider reducing intake to <200 mg/day. Dihydrocodeine: Increased volume of distribution and clearance in pregnancy; dose may need titration but no established guidelines. Use lowest effective dose for shortest duration.
ERGOSTAT (ergonovine) is an ergot alkaloid used for postpartum hemorrhage. It causes sustained uterine contraction. Contraindicated in hypertension, preeclampsia, and vascular disease. Administer IM or IV slowly over 1 minute to avoid severe vasoconstriction. Monitor blood pressure and uterine tone closely. Do not use in patients with hypersensitivity to ergot alkaloids.
Dihydrocodeine is a prodrug requiring CYP2D6 metabolism to active metabolites; poor metabolizers may have reduced efficacy while ultrarapid metabolizers risk toxicity. Caffeine potentiates analgesia and may cause insomnia with evening use. Do not exceed 8 tablets per 24 hours due to acetaminophen hepatotoxicity risk. Use with caution in elderly and patients with renal impairment.
This medication is given to control bleeding after childbirth.,It may cause nausea, vomiting, or dizziness.,Report severe headache, chest pain, or vision changes immediately.,Avoid smoking or using nicotine products while on this drug.,Do not breastfeed within 12 hours after the last dose; discuss with your doctor.
Take with food if stomach upset occurs.,Avoid alcohol and products containing acetaminophen to prevent liver damage.,Do not exceed 8 tablets in 24 hours.,May cause drowsiness; avoid driving or operating machinery until you know how this medication affects you.,If you have a history of drug dependence, use with caution as dihydrocodeine can be habit-forming.
No interactions on record
"The combination of chlordiazepoxide, a benzodiazepine that enhances GABAergic inhibition, and dihydrocodeine, an opioid agonist primarily at mu-receptors, results in additive central nervous system (CNS) depression. This synergy increases the risk of profound sedation, respiratory depression, coma, and death, particularly in vulnerable populations such as the elderly or those with pre-existing respiratory compromise. Concurrent use also elevates the potential for hypotension and psychomotor impairment, leading to falls or accidents."
"Reserpine depletes catecholamines in the central nervous system and peripheral adrenergic neurons, leading to reduced sympathetic outflow. Dihydrocodeine, an opioid agonist, can cause further central nervous system depression and hypotension. When combined, there is an additive risk of excessive hypotension, bradycardia, and profound sedation, potentially leading to falls or respiratory depression."
"Dihydrocodeine, an opioid analgesic, undergoes O-demethylation primarily via CYP2D6 to form dihydromorphine, which contributes to its analgesic effects. Clemastine, a first-generation antihistamine, is metabolized mainly by CYP2D6 as well. When co-administered, clemastine competitively inhibits CYP2D6, reducing the clearance of dihydrocodeine and decreasing the formation of the active metabolite dihydromorphine. This can lead to diminished analgesic efficacy and potentially increased levels of parent dihydrocodeine, heightening the risk of opioid-related adverse effects such as respiratory depression, sedation, and constipation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERGOSTAT vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, answered by our medical review team.
ERGOSTAT is a Ergot Alkaloid Antimigraine that works by Ergostat (ergotamine) is a serotonin (5-HT) receptor agonist, specifically at 5-HT1B and 5-HT1D receptors, leading to cranial vasoconstriction and inhibition of neurogenic inflammation. It also has partial agonist/antagonist activity at alpha-adrenergic receptors.. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is a Opioid Agonist that works by Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERGOSTAT and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERGOSTAT is: 0.2 mg intramuscularly or intravenously every 2-4 hours for maximum 5 doses; not to exceed 1 mg total dose.. The standard adult dose of ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is: 1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERGOSTAT and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERGOSTAT is classified as Category C. Ergostat (ergonovine) is contraindicated in pregnancy due to its potent uterotonic effects, which can cause uterine tetany, fetal hypoxia, and placental abruption. It is classified. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.